Uvealni melanom
Recommendations for diagnosis, treatment and follow-up of patients with uveal melanoma

priporočila zdravljenja

Authors

  • Barbara Perić Onkološki inštitut Ljubljana ; Univerza v Ljubljani, Medicinska fakulteta
  • Gregor Hawlina Univerzitetni klinični center Ljubljana, Očesna klinika
  • Vladimir Debelič Univerzitetni klinični center Ljubljana, Očesna klinika
  • Janja Ocvirk Onkološki inštitut Ljubljana ; Univerza v Ljubljani, Medicinska fakulteta
  • Martina Reberšek Onkološki inštitut Ljubljana ; Univerza v Ljubljani, Medicinska fakulteta
  • Marko Kokalj Onkološki inštitut Ljubljana
  • Gaber Plavc Onkološki inštitut Ljubljana
  • Vesna Zadnik Onkološki inštitut Ljubljana ; Univerza v Ljubljani, Medicinska fakulteta
  • Alenka Lavrič Groznik Univerzitetni klinični center Ljubljana, Očesna klinika

DOI:

https://doi.org/10.25670/oi2025-007on

Keywords:

uveal melanoma, treatment, multidisciplinary management, recommendations

Abstract

Uvealni melanom je najpogostejši primarni maligni znotrajočesni tumor pri odraslih. Med uvealne melanome uvrščamo melanom žilnice (90 %), ciliarnika (6 %) in šarenice (4 %). Med leti 2017 in 2021 je za uvealnim melanomom v Sloveniji letno zbolelo povprečno 23 oseb, kar predstavlja 3,7 % vseh melanomov. Prva slovenska celostna in multidisciplinarna priporočila zdravljenja vključujejo melanome žilnice in ciliarnika in so povzeta po
ameriških smernicah NCCN. Priporočila celostno predstavijo
tako dejavnike tveganja, kot klinično sliko in možnosti lokalnega zdravljenja tega raka, kot tudi sodobne načine multidisciplinarnega zdravljenja oddaljenih zasevkov vključno z možnostjo genotipizacije polne krvi na prisotnost človeškega levkocitnega antigena (HLA)-A*02:01).
S priporočili želimo specialistom različnih strok olajšati tako
pogovor z bolnikom in svojci, kot izbiro ustreznega zdravljenja.


Abstract (Eng)

Uveal melanoma is the most common primary malignant intraocular tumor in adults. Uveal melanomas include choroidal melanoma (90%), ciliary body melanoma (6%), and iris melanoma (4%). Between 2017 and 2021, an average of 23 people were diagnosed with uveal melanoma annually in Slovenia, representing 3.7% of all melanomas.
The first comprehensive and multidisciplinary treatment guidelines in Slovenia cover choroidal and ciliary body melanomas and are based on the American NCCN guidelines. These recommendations provide a holistic overview of risk factors, clinical presentation, and
local treatment options for this cancer, as well as modern approaches to the multidisciplinary management of distant metastases—including the possibility of full blood genotyping for the presence of the human leukocyte antigen (HLA)-A*02:01. The aim of these guidelines is to support specialists from various fields in both communicating with patients and their families, and in
choosing the most appropriate treatment options.

Downloads

Published

2025-06-09

How to Cite

Perić, B., Hawlina , G., Debelič , V., Ocvirk , J. ., Reberšek , M., Kokalj, . M., Plavc , G., Zadnik , V., & Lavrič Groznik , A. (2025). Recommendations for diagnosis, treatment and follow-up of patients with uveal melanoma: priporočila zdravljenja. Onkologija : Slovenian Journal of Oncology, 29(1), 46–55. https://doi.org/10.25670/oi2025-007on

Issue

Vol. 29 No. 1 (2025)

Section

Guidelines

License

Copyright (c) 2025 Barbara Perić, Gregor Hawlina , Vladimir Debelič , Janja Ocvirk , Martina Reberšek , Marko Kokalj, Gaber Plavc , Vesna Zadnik , Alenka Lavrič Groznik

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.